SLRN ACELYRIN Inc.: Long-Term Debt to Capital Coefficient

Acelyrin, Inc. (SLRN) management is currently undergoing a painful restructuring period following a change in top executives due to R&D failures. The market dynamics reflected in the price action, where the indicator stands at 0.01, are further compounded by risks of sanctions pressure on raw material logistics and complications with foreign patents. The development of this diversified pharmaceutical business relies on the volume of investment and the successful validation of new drug efficacy during testing.

SLRN - Acelyrin Inc. Long-Term Debt to Equity over the range 02/21/2024 - 05/31/2025

Comprehensive metric breakdowns and analytics for Acelyrin, Inc. (SLRN)

- price and consensus price forecast:
Quote Chart Acelyrin Inc.|SLRN - Analyst Consensus Forecast
- market capitalization data:
Market Value Acelyrin, Inc.|SLRN - Enterprise Value
- book capitalization data:
Book Value per Share ACELYRIN|SLRN - Company Book Value|Market Value to Book Value acelyrin.com|SLRN - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Acelyrin, Inc.|SLRN - Long-Term Debt to Capital|Short-Term Debt to Capital acelyrin.com|SLRN - Company Total Debt|Debt to Net Assets Ratio Acelyrin, Inc.|SLRN - Company Long-Term Debt|Short-Term Debt ACELYRIN
Initial company analysis:Acelyrin Inc.

This indicator measures the share of long-term liabilities within the business's market value structure to determine the level of financial risk. The metric assesses the company's dependence on external borrowings during capital formation. The virtual development model of Acelyrin, Inc. (SLRN), which outsources synthesis to CMO sites, minimizes the need for capital expenditures. By analyzing the ratio of long-term debt to equity, an investor can gauge the efficiency of leverage management. This allows for an assessment of the portfolio's resilience to credit shocks.

Who Acelyrin, Inc. competes with

Long-Term Liabilities to Equity Haleon PLC|Kenvue Corp (KVUE) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Verona Pharma Inc. (VRNA)|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|ligand.com - Long-Term Debt to Capital|Long-Term Debt to Equity Amneal (AMRX)|PRGO: Long-Term Debt to Capital Coefficient|ALVO (Alvotech Corp) - Long-Term Debt to Equity|Liquidia Inc. (LQDA) - Long-Term Debt to Equity Ratio|GLPG (Galapagos NV) - Long-Term Debt to Capital|Long-Term Debt to Capital anipharmaceuticals.com (ANIP)|MannKind (MNKD) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient AMPH (Amphastar Pharmaceuticals Inc)|PCRX: Long-Term Debt to Equity|SPRY - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Theravance Biopharma TBPH|AQST - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital scpharmaceuticals.com SCPH|Tectonic Therapeutic (TECX) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital TNXP (Tonix Pharmaceuticals Inc.)|Long-Term Liabilities to Capital SXTC|Eupraxia Pharmaceuticals (EPRX) - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient bioharvest.com (BHST)|Long-Term Debt to Capital EXOZ (eXoZymes)|Long-Term Debt to Capital Oramed ORMP|ENTX: Long-Term Debt to Capital|HYFT - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital ABVC|CPIX (cumberlandpharma.com) - Long-Term Liabilities to Capital|Long-Term Debt to Equity Quantum BioPharma|Long-Term Debt to Equity FibroGen Inc (FGEN)|Telomir Pharma - Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital RANI (ranitherapeutics.com)|Long-Term Debt to Equity Synergy CHC|Long-Term Debt to Capital Coefficient Rallybio Corp RLYB|Long-Term Debt to Capital LEXX (Lexaria)|PULM: Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ftzy.com.cn|Long-Term Debt to Capital Ratio Aptorum Group|LYRA - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient impactbiomedinc.com|TNFA (TNF Pharmaceuticals) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital YCBD (cbdmd.com)|PRFX - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio Altamira Therapeutics Ltd CYTO|LIPO: Long-Term Debt to Capital|optinose.com (OPTN) - Long-Term Debt to Equity Ratio|Pieris Pharmaceuticals, Inc. - Long-Term Debt to Equity Ratio|PROC (Procaps Group) - Ratio of Long-Term Indebtedness to Capital|PTPI: Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital QLI|Long-Term Debt to Equity TFF Pharmaceuticals (TFFP)